Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 68Ga-R8760 in ACC and Healthy Volunteers
NCT05999292Phase 1Terminated
- Sponsor
- Radionetics Oncology
- Start
- Sep 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-R8760 in adrenocortical carcinoma (ACC) (2 arms), sponsored by Radionetics Oncology. Primary endpoints: Incidence of adverse events at 7 days, Absorbed dose coefficients at 1 day and 1 more. Started Sep 2023; status: terminated.
02
Drugs
68Ga-R8760
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT05999292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999292.